Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study

1 Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate): drug safety communication-safety review of post-market reports of serious bleeding events. http://www.fda. gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm 282820.htm. Accessed 10 March 2012. 2 Therapeutic Goods Administration, Australia. Dabigatran (Pradaxa): risk of bleeding relating to use. http://www.tga. gov.au/safety/alertsmedicine-dabigatran-111005.htm. Accessed 10 March 2012. 3 EuropeanMedicines Agency. EuropeanMedicines Agency updates on safety of Pradaxa [press release]. http://www.ema. europa.eu/docs/ en_GB/document_library/Press_release/2011/11/WC500117818.pdf. Accessed 10 March 2012. 4 The ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066–78. 5 Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, FlakerG, AvezumA,Hohnloser SH,DiazR, TalajicM, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–17. 6 ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–125. 7 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–51. 8 Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–926. 9 Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, FranzosiMG,Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-term anticoagulant Therapy (RE-LY) Trial. Circulation 2011; 123: 2363–72. 10 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67. 11 Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975–83. 12 Wang TJ,Massaro JM, Levy D, Vasan RS,Wolf PA, D Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the FraminghamHeart Study. JAMA 2003; 290: 1049–56.